ストックスクリーナーアプリを入手
3.56
1.57%
0.05
前日終値:
$3.51
開ける：
$3.52
24時間の取引高:
778.57K
Relative Volume:
0.45
時価総額：
$237.55M
収益：
$80.00M
当期純損益:
$-76.12M
株価収益率:
-3.1051
EPS:
-1.1465
ネットキャッシュフロー:
$-63.88M
1週間 パフォーマンス:
+1.28%
1か月 パフォーマンス:
-46.71%
6か月 パフォーマンス:
-71.48%
1年 パフォーマンス:
-47.57%
1日の値動き範囲:
$3.51
$3.63
1週間の範囲:
$3.34
$3.64
52週間の値動き範囲:
$2.83
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
名前
Fulcrum Therapeutics Inc
セクター
電話
617-651-8851
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
3.565 | 233.88M | 80.00M | -76.12M | -63.88M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
446.71 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
608.29 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.17 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.48 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-12 | 開始されました | JP Morgan | Overweight |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-07-29 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-09-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | ダウングレード | Stifel | Buy → Hold |
| 2024-09-09 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-09-25 | 開始されました | Goldman | Neutral |
| 2023-08-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | アップグレード | Stifel | Hold → Buy |
| 2023-05-04 | ダウングレード | Goldman | Buy → Neutral |
| 2023-03-10 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | ダウングレード | Stifel | Buy → Hold |
| 2023-02-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 開始されました | Goldman | Buy |
| 2022-03-08 | 開始されました | Oppenheimer | Outperform |
| 2022-03-03 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-08-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-22 | 開始されました | Credit Suisse | Outperform |
| 2021-03-02 | 開始されました | Stifel | Buy |
| 2020-10-16 | 開始されました | Piper Sandler | Overweight |
| 2020-08-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2019-10-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-08-12 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Fulcrum Therapeutics Inc (FULC) 最新ニュース
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect - ACCESS Newswire
Fulcrum plunges after discontinuing lead program - MSN
What's going on with Fulcrum Therapeutics stock on Thursday? - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Fulcrum Therapeutics, Inc. Files Form 8-K Report with SEC – Company Information and Key Details (June 2026) - Minichart
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits
Fulcrum Therapeutics Advances Restructuring with Leadership Changes - TipRanks
Fulcrum Therapeutics (NASDAQ: FULC) adds change-in-control pay, finance chief to depart - Stock Titan
Fulcrum Therapeutics, Inc. Announces Departure of Greg Tourangeau, Principal Accounting Officer - marketscreener.com
A Cambridge biotech had hundreds of millions in the bank — then the FDA pulled the plug on its only drug and 85% of its staff lost their jobs - Yahoo Finance
Tang entities report 5,451,800‑share stake in Fulcrum (FULC) - Stock Titan
FULC stock crashes as cancer risk forces its only drug program's end - MSN
Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) - NewMediaWire
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encour - The National Law Review
Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations - NewMediaWire
Fulcrum Therapeutics, Inc. (FULC) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations - NewMediaWire
Layoff Tracker: Fulcrum axes 85% of staff after walking away from lead asset - BioSpace
Fulcrum Therapeutics (FULC) loses 51% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Investors to Inquire about Securities Investigation - ACCESS Newswire
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
What's Going On With Fulcrum Therapeutics Stock On Thursday? - Sahm
Fulcrum Therapeutics lays off 85% of workforce as it seeks strategic alternatives - The Business Journals
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Reach Out - ACCESS Newswire
A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring - Yahoo Finance
Levi & Korsinsky Announces Investigation of Securities Claims Against Fulcrum Therapeutics, Inc. (FULC) - GlobeNewswire
Fulcrum Therapeutics Undertakes Major Restructuring, Explores Strategic Alternatives - TipRanks
Fulcrum Therapeutics (FULC) cuts workforce 85% and hires Leerink for strategic review - Stock Titan
Fulcrum Therapeutics, Inc. Engages Leerink Partners LLC as Financial Advisor to Assist in Reviewing Potential Strategic Alternatives - marketscreener.com
FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud - Business Wire
Fulcrum Therapeutics to Cut Most of Staff After Ending Sickle-Cell-Drug Development - Moomoo
FULC Downgraded by JP Morgan -- Rating Changed to Underweight - GuruFocus
Fulcrum: 'Hold' On Pociredir Discontinuation And Strategic Alternatives Shift - Seeking Alpha
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End - sharewise.com
FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum T - GuruFocus
This Truist Securities Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday - Benzinga
FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations - Moomoo
JPMorgan Downgrades Fulcrum Therapeutics to Underweight From Overweight - marketscreener.com
Goldman Sachs drops Fulcrum Therapeutics stock coverage after trial halt By Investing.com - Investing.com Australia
FULC Downgraded by Stifel -- Price Target Lowered to $3.00 - GuruFocus
Goldman Sachs drops Fulcrum Therapeutics stock coverage after trial halt - Investing.com UK
Goldman Sachs Suspends Rating on Fulcrum Therapeutics (FULC) - GuruFocus
Fulcrum Therapeutics Inc (FULC) 財務データ
収益
当期純利益
現金流量
EPS
1.61%
大文字化:
|
ボリューム (24 時間):